首页> 外文期刊>Skin pharmacology and physiology >Hydrocortisone aceponate activity and benefit/risk ratio in relation to reference topical glucocorticoids.
【24h】

Hydrocortisone aceponate activity and benefit/risk ratio in relation to reference topical glucocorticoids.

机译:相对于参考局部糖皮质激素而言,氢化可的松醋酮的活性和获益/风险比。

获取原文
获取原文并翻译 | 示例
       

摘要

The evaluation of the benefit/risk ratio (BRR) for topical glucocorticoids (TGC) allows the comparison of active ingredients and thereby includes aspects of dosage (blanching response, BR) as well as adverse effects (skin atrophy). In the present study, the BRR of hydrocortisone aceponate, prednicarbate and betamethasone valerate was investigated according to an adapted procedure for investigating the BR. The main difference is the longer application period of the investigational substance without occlusion. Thus, the pharmacokinetic characteristics of all of the systems are considered more intensely and the penetration conditions are designed in a realistic way, namely oriented towards the preparation in order to improve the significance and relevance of the BRR for practical use. The results demonstrate that the investigated substances also show differences in the extent of the BR, but on the other hand they show that the improved penetration characteristics of the double-esterified compounds are clearly less effective. In comparison to the BRR, this results to a large extent in a balanced picture without relevant advantages for single preparations. Nevertheless, the already mentioned positive characteristics of the investigated TGC and the positive practical clinical experiences have been approved. Further investigations have to show whether the method presented here for investigating the BR offers advantages in the comparative assessment of TGC.
机译:对局部糖皮质激素(TGC)的获益/风险比(BRR)的评估可以比较活性成分,从而包括剂量(灼热反应,BR)以及不良反应(皮肤萎缩)方面。在本研究中,根据适应性研究BR的方法,研究了氢化可的松乙酰丙酮,强的碳酸氢根和戊酸倍他米松的BRR。主要区别是没有堵塞的研究物质的使用期限更长。因此,所有系统的药代动力学特性都被更加强烈地考虑,并且以现实的方式设计渗透条件,即以制备为导向,以提高BRR在实际应用中的意义和相关性。结果表明,所研究的物质在BR的范围上也存在差异,但另一方面,它们表明,双酯化化合物改善的渗透特性显然无效。与BRR相比,这在很大程度上是平衡的结果,而没有单一制剂的相关优势。然而,已经被研究的TGC的已经提到的积极特征和积极的实际临床经验已经被批准。进一步的研究必须表明,此处介绍的研究无线电通信局的方法在TGC的比较评估中是否具有优势。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号